Holdenrieder S - Search Results

1

Clinically Meaningful Use of Blood Tumor Markers in Oncology.

Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F. Holdenrieder S, et al. Biomed Res Int. 2016;2016:9795269. doi: 10.1155/2016/9795269. Epub 2016 Nov 30. Biomed Res Int. 2016. PMID: 28042579 Free PMC article. Review.

2

Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer.

Yörüker EE, Holdenrieder S, Gezer U. Yörüker EE, et al. Among authors: holdenrieder s. Clin Chim Acta. 2016 Apr 1;455:26-32. doi: 10.1016/j.cca.2016.01.016. Epub 2016 Jan 18. Clin Chim Acta. 2016. PMID: 26797671 Review.

3

In Response to "Serum Tumor Marker Use in Patients With Advanced Solid Tumors".

Dayyani F, Morgenstern D, Holdenrieder S. Dayyani F, et al. Among authors: holdenrieder s. J Oncol Pract. 2016 Mar;12(3):273-4. doi: 10.1200/JOP.2015.009241. Epub 2016 Feb 2. J Oncol Pract. 2016. PMID: 26837562 No abstract available.

4

Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis.

Holdenrieder S, Wehnl B, Hettwer K, Simon K, Uhlig S, Dayyani F. Holdenrieder S, et al. Br J Cancer. 2017 Apr 11;116(8):1037-1045. doi: 10.1038/bjc.2017.45. Epub 2017 Mar 9. Br J Cancer. 2017. PMID: 28278517 Free PMC article. Review.

5

Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.

Dolscheid-Pommerich RC, Keyver-Paik M, Hecking T, Kuhn W, Hartmann G, Stoffel-Wagner B, Holdenrieder S. Dolscheid-Pommerich RC, et al. Among authors: holdenrieder s. Tumour Biol. 2017 Oct;39(10):1010428317730246. doi: 10.1177/1010428317730246. Tumour Biol. 2017. PMID: 29034816 Free article.

6

Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer.

Holdenrieder S, Molina R, Qiu L, Zhi X, Rutz S, Engel C, Kasper-Sauer P, Dayyani F, Korse CM. Holdenrieder S, et al. Tumour Biol. 2018 Apr;40(4):1010428318772202. doi: 10.1177/1010428318772202. Tumour Biol. 2018. PMID: 29701125 Free article.

7

A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test.

Muley T, Zhang X, Holdenrieder S, Korse CM, Zhi XY, Molina R, Liu Z, Hartmann G, van den Heuvel MM, Qian K, Marrades R, Engel C, He Y, Wehnl B, Dayyani F, Herth F. Muley T, et al. Among authors: holdenrieder s. Tumour Biol. 2020 Sep;42(9):1010428320958603. doi: 10.1177/1010428320958603. Tumour Biol. 2020. PMID: 32964798 Free article.

8

Apoptotic markers in cancer.

Holdenrieder S, Stieber P. Holdenrieder S, et al. Clin Biochem. 2004 Jul;37(7):605-17. doi: 10.1016/j.clinbiochem.2004.05.003. Clin Biochem. 2004. PMID: 15234242 Review.

9

Clinical relevance of tumor markers for the control of chemotherapy.

Finek J, Holubec L Jr, Topolcan O, Salvet J, Pikner R, Holdenrieder S, Stieber P, Lamerz R, Holubec Sen L, Svobodova S, Visokai V, Helmichova E. Finek J, et al. Among authors: holdenrieder s. Anticancer Res. 2005 May-Jun;25(3A):1655-8. Anticancer Res. 2005. PMID: 16035152 Free article.

10

Diagnostic relevance of circulating biomarkers in patients with lung cancer.

Molina R, Holdenrieder S, Auge JM, Schalhorn A, Hatz R, Stieber P. Molina R, et al. Among authors: holdenrieder s. Cancer Biomark. 2010;6(3-4):163-78. doi: 10.3233/CBM-2009-0127. Cancer Biomark. 2010. PMID: 20660962 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

271 results

Search Page